Boston Scientific presented data from the Champion-AF trial showing that Watchman FLX provided superior protection from bleeding compared with non-vitamin K oral anticoagulants in atrial fibrillation patients. The device also demonstrated noninferiority versus NOACs on clinical outcomes including stroke, cardiovascular death, or systemic embolism. The left atrial appendage closure device is intended to reduce thromboembolic risk while avoiding long-term anticoagulation complications. In trial comparisons, bleeding differences can be decisive for both physician adoption and guideline-based decision-making. The coverage also notes that while the overall stroke composite met noninferiority expectations, signals around strokes were a point of attention among observers. That emphasis reflects the high bar for stroke outcomes in AF device studies. Overall, the data strengthens the evidentiary package for Watchman FLX in a competitive field of LAA closure alternatives seeking to match or exceed NOAC performance while improving safety profiles.